retatrutide fda approval date vs Tirzepatide vs Semaglutide FDA approves Retatrutide this year?

This symptom may arise through several mechanisms, including low blood glucose (hypoglycaemia), dehydration from gastrointestinal effects, orthostatic hypotension, or reduced caloric intake

The most recently approved FDA medication for the treatment of obesity, tirzepatide, exerts its physiologic effects as a dual GLP-1R and Gastric Inhibitory Polypeptide Receptor (GIP-R) agonist with better efficacy than the standalone GIP-R agonist semaglutide [39]

Effet modeste mais rel sur la scrtion de GLP-1

Simon-Szab, L., Kokas, M., Mandl, J., Kri, G

A useful benchmark is less than 1% of starting body weight lost per month at a stable dose